The world of diabetes management is growing at an expeditious rate, so how do we define progress in this space? Great question, and one I couldn’t resolve myself so I brought in past podcast guest and fellow T1D, Mark Carter, who has worked within the industry. We had the pleasure of sitting with three insulin pump therapy leaders: Michael Hill, VP of Global Portfolio Marketing at Medtronic; Dr. Trang Ly, Senior Vice President and Medical Director at Insulet; and Dr. Steph Habif, a behavioral scientist at Tandem.
Our conversation is packed with insights on how to define progress in daily diabetes management while addressing some of the community’s most burning questions. Stay tuned for part #2.
The Real Life Diabetes Podcast has worked with a ton of brands who make life with diabetes a more pleasant one. If you would like to learn more about advertising opportunities or sponsorships, please contact Penelope, penelope@diabetesdailygrind(dot)com.
Mark Carter is an Assistant Vice President (Business Development/Merchant Services) with First Security Bank. His background in commercial property management, leadership development and being a former TM for Eli Lilly, Insulet (Omni Pod) and Medtronic Diabetes gives him a unique perspective when helping others talk through managing diabetes in the day to day life.
Dr. Steph Habif is a behavioral scientist with 20 years experience in health technology. She currently serves as the Vice President of Behavioral Sciences at Tandem Diabetes Care, where she oversees human factors, clinical and behavioral research teams, and contributes to the overall strategic direction of the company. Steph has held faculty appointments at Stanford University, Columbia University in New York, and Victoria University in Melbourne, Australia. She loves to eat grilled cheese sandwiches.
Michael Hill leads the global portfolio marketing team at Medtronic Diabetes with an upstream focus on advancing the product innovation roadmap based on global voice of customer working seamlessly with the global commercial regions and the product innovation team. He also leads critical global customer digital transformation work to ensure creation of a seamless digital ecosystem to help further advance customer experience innovation. The group’s goal is to ensure a data-driven approach to strategy informed by patient insights and to ensure tight coordination of all the respective functions. Michael earned a Bachelor of Science in Mechanical Engineering from the Massachusetts Institute of Technology, and an MBA from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar.
Dr. Trang Ly has served as our Senior Vice President and Medical Director since February 2018. From September 2016 to February 2018, she served as our Vice President and Medical Director. Dr. Ly is a renowned expert in artificial pancreas and diabetes technologies. Most recently, she served as Clinical Assistant Professor in the Division of Pediatric Endocrinology, Stanford University School of Medicine. Prior to her time at Stanford, Dr. Ly was a Pediatric Endocrinologist in the Department of Endocrinology and Diabetes at Princess Margaret Hospital for Children in Perth, Australia. Dr. Ly holds a Bachelor of Medicine and Surgery, a Diploma of Child Health and a PhD in Pediatrics from the University of Western Australia. She is also a fellow of the Royal Australasian College of Physicians, with specialist qualification in Pediatric Endocrinology.